NEW YORK, March 3, 2021 /PRNewswire/ — atai Life Sciences (“atai” or the “Company”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $157 million Series D financing round. The round was led by our existing investors Apeiron Investment Group, the family office of atai’…

Source

Previous articleRed Light Holland’s iMicro Digital Care App Launches Virtual Telecounseling with a Membership Program Led by Certified Therapist and Microdosing Expert
Next articleMINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury